Skip to main content

Advertisement

Table 2 Outcomes of patients who discontinued prophylaxis before and after cd4 count increase to 200 cells/μl and patients who did not initiated prophylaxis for pneumocystosis

From: Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy

Outcome Primary prophylaxis Secondary prophylaxis No prophylaxis
  CD4 <200/μL CD4 200/μL P value CD4 <200/μL CD4 200/μL P value  
Patient number, n 211 68   145 71   165
New/recurrent episodes of PCP, n 11 1   6 1   3
Time from discontinuation of prophylaxis to PCP, median, M 13.7 (2.2-92.4) 74.5   22.8 (8.3-69.3) -20.7   
CD4 count when new PCP developed, median, cells/μl 33 (8-138) 9   4 (1-40) -13   5 (0-87)
Total observation duration, PY 366 234   241 210   104
Incidence of new/recurrent PCP, per 100 PY (95% CI) 3.00 (1.26-4.76) 0.43 (0.01-2.38) 0.03 2.49 (0.91-5.42) 0.48 (0.01-2.65) 0.13 2.88 (0.59-8.43)
Episodes of bacterial infection, n 53 13   21 7   22
Incidence of bacterial infection, per 100 PY (95% CI) 14.48 (10.85-18.94) 5.56 (2.96-9.50) <0.001 8.71 (5.39-13.32) 3.33 (1.34-6.87) 0.03 21.16 (13.35-32.03)
Episodes of parasitic infection, n 2 0   2 0   2
Incidence of parasitic infection, per 100 PY (95% CI) 0.54 (0.07-1.97) 0   0.83 (0.10-3.00) 0   1.92 (0.23-6.95)
Death, n (%) 23 (10.9) 4 (5.9) 0.35 8 (5.5) 1 (1.4) 0.28 22 (13.3)
Patients lost to follow-up, n (%) 40 (19.0) 7 (10.3) 0.19 16 (11.0) 8 (11.3) 1 44 (26.6)
  1. Abbreviations: CI, confidence interval; PCP, Pneumocystis jirovecii pneumonia; PY, persons-years